NeuExcell Therapeutics participates in Series Pre-A to raise over $10M

By Patrick Miller |

Renowned gene therapy company, NeuExcell Therapeutics, that is known to exclusively focus on neurodegenerative diseases, has reportedly declared a USD 10+ million Series Pre-A financing round. The round was led by Co-Win Ventures, although other institutional investors such as InnoAngel, YuanBio, Tsingyuan, and Oriza Seed joined the same.

With the closure of this successful round, NeuExcell is thrilled to welcome Jonathan Sun and Dr. Xin Huang to the Board of Directors.

Peter Tombros, Board Chair, NeuExcell Therapeutics, has been quoted to state that the company is honored to welcome this reputable band of investors, whose support and valuable experience will help NeuExcell leverage its proprietary neuroregenerative gene therapy platform spanning numerous neurodegenerative indications. The capital raised through this financing is an indication of the company’s growth strategy and validates its science within the biotech space, Tombros added.

Professor Gong Chen, Co-founder and Chief Scientific Advisor, NeuExcell Therapeutics, has reportedly stated that the company is thrilled regarding the growth prospects of its innovative technology that is designed to bring forth effective therapies to numerous patients worldwide.

According to Dr. Xin Huang, Managing Partner, Co-Win Ventures, investing in this Pre-A financing round is a brilliant opportunity for the company to be a part of an experienced leadership. NeuExcell’s proprietary technology possesses the potential to be a platform for the treatment of many neurodegenerative diseases, thereby offering hope to path-breaking therapies to patients, Huang added.

About NeuExcell Therapeutics

A privately held gene technology company, NeuExcell’s mission is to bring about enhanced treatments for patients afflicted with CNS injuries and neurodegenerative diseases. It has its headquarters in Shanghai, China and Pennsylvania, USA.

The firm has developed a disruptive neural repair technology, via astrocyte-to-neuron conversion in vivo, based on the work of Prof. Gong Chen, by introducing neural transcription factor(s) through AAV (adeno-associated virus)-based gene therapy. The company’s product portfolio covers key neurodegenerative diseases like Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS), Stroke, Alzheimer’s Disease, Huntington’s disease, Parkinson’s Disease, Spinal Cord Injury, and Glioma.



Source Credits:

https://apnews.com/press-release/pr-newswire/technology-health-3f2f069fad2c6b67911efd597e0891d5

Comments

Post a Comment

Add your comment here

Popular posts

UK PM and Bill Gates announce new green partnership

By Hope Hill |
U.S. business magnate Bill Gates and UK Prime Minister Boris Johnson have made it to the headlines for announcing a new partnership between the government and the Breakthrough Energy Catalyst. The deal entails a substantial amount to be invested in next-gen clean energy technologies. For the unversed, Catalyst is a vital program within the Breakthrough Energy network and brings together a variety of parties – businesspersons, philanthropists, and governments, to invest in climate technologies. Catalyst focuses on four major green technology areas including long term energy storage, direct air capture, green hydrogen, and sustainable aviation fuels. As per sources, the UK government has already pledged to commit GBP 200 million to develop UK projects in these four areas as a part of the GBP 1 billion Net Zero Innovation Portfolio. Businesses that have had tie-ups with the Breakthrough Energy Catalyst will match fund GBP 200 million of that investment to help market these technologies...
Read more

Mars embarks on new initiative to reduce GHG emissions across value chain

By Patrick Miller |
Mars, Incorporated, has declared that it has a new mission in mind. The company has strengthened its commitment to accomplish a state of net zero GHG emissions spanning its overall value chain, by the year 2050. Mars’ mission aligns with the prestigious Paris Agreement, one of the most ambitious climate change action plans, that aims to limit global temperature rises up until 1.5 °C. Grant F. Reid, Chief Executive Officer, Mars, has some real-time insights into the present climate change situation. He has been quoted to state that faster initiatives must be taken at this point of time, since climate change is already well on its way to affecting people and to eliminate this threat, net zero targets must be implemented seamlessly, across whole distribution networks and the results must be depicted soon enough, instead of having to waiting for ages. Reid acknowledges the fact that a lot of loopholes exist in some net zero commitments that reduce their credibility and at large, the cli...
Read more

Munters signs turnkey project to build lithium battery laboratory

By Patrick Miller |
Energy and climate solutions leader Munters has reportedly signed a turnkey project agreement entailing the construction of a laboratory in Scandinavia. As per sources, the company plans to design and build a lithium battery laboratory in the Scandinavian region, strengthening its position as a major supplier to lithium battery producers. Munters’ step ahead may be an action initiated in favor of climate change that is increasing the demand for lithium batteries the world over. Munters’ ability to build the unit and its competence to ensure appropriate execution of the construction was a major requirement by the client. As per terms and conditions, the company will deliver the project over the forthcoming six months. The project valuation adds up to around MSEK 83.5. Klas Forsström, President and Chief Executive Officer, Munters, has been quoted to state that with increasing focus being given on minimizing carbon emissions, there’s a strong megatrend of sustainability in the market...
Read more